Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Proph says...."The merger with AEZS arguably values.....
View:
Post by Minty_33 on Jan 22, 2024 10:40pm

Proph says...."The merger with AEZS arguably values.....

CZO's shares at $1.25 given H.C. Wainwright's US$15 target price for AEZS".

AND the current share price is $1.98 so CZO stock is essentially getting cut in half. FUTHERMORE H.C Wainwright are notorious for dumping their stock on shareholders. They have a 1.8 stars out of 5 on Google Reviews. Would you go to a restaurant or a weeks vacation at a resort with those ratings? So why would anyone believe these clowns?

Garbage Company and beqare of bs pumpers like used prophylactic
Comment by prophetoffactz on Jan 22, 2024 11:37pm
AEZS's diagnostic test was to complete pediatric trial enrollement in December 2023. The pediatric clinical trial data, expected regulatory approval this year, and a new North American licensing deal should drive AEZS towards H.C. Wainwright's US$15 target. Gilles is on the Board of Directors of AEZS and should have a very good idea concerning the deal expected to be signed. The test is ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities